# US 2010/0168105 A1 · Spirocyclopropyl Piperidine Derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168105 A1
- Document ID: US20100168105A1
- Status: Published application
- Kind: A1
- Application number: 12/601,308
- Filed: 2008-05-23
- Published: 2010-07-01
- Earliest claimed: 2007-05-25
- Assignees: Astrazeneca AB
- Inventors: Peter Bernstein; Dean Brown; Joseph Cacciola; Phil Edwards; James Folmer; Thierry Groblewski; Mark Sylvester; Steven Wesolowski
- Web page: https://patentgrep.com/patent/US20100168105A1

## CPC

- C07D 221/20: Spiro-condensed ring systems
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 25/34: Tobacco-abuse
- A61P 25/36: Opioid-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein is at least one piperidine derivative, at least one pharmaceutical composition comprising at least one piperidine derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith

## Claims

### Claim 1

A compound of formula I, enantiomers thereof, pharmaceutically acceptable salts thereof, or mixtures thereof:
wherein:
R1 is aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, heterocycloalkylalkyl, alkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, aminocarbonylalkyl, heterocycle, arylalkenyl, or heterocycloalkyl; wherein R1 is optionally substituted with at least one substituent selected independently from alkyl, cyano, sulfinyl, haloalkyl, amide, alkoxy, halogen, arylalkoxy, alkylcarbonyl, carboxy (—C(═O)OH), hydroxy (—OH), amino, alkoxycarbonyl, and alkylsulfonyl; and
R2 is aryl, heteroaryl, cycloalkyl, alkyl, heterocycloalkyl, or cycloalkylalkyl; wherein R2 is optionally substituted with at least one substituent selected independently from C1-C6alkyl, alkoxy, and cycloalkyl;
with the provisos that:
1) when R2 is a cyclohexyl, R1 is not a substituted or unsubstituted phenyl;
2) when R2 is aryl, R2 is not unsubstituted phenyl; and
3) when R1 is tetrahydropyran-4-yl and R2 is a substituted phenyl, the substituted phenyl is not ortho- or meta-substituted with methyl or meta-substituted with methoxy.

### Claim 2 (depends on 1)

A compound according to claim 1, enantiomers thereof, pharmaceutically acceptable salts thereof, or mixtures thereof, wherein R1 is aryl, heteroaryl, arylalkyl, cycloalkyl, heterocycloalkylalkyl, alkyl, arylalkenyl, heterocycle, or heterocycloalkyl.

### Claim 3 (depends on 1)

A compound according to claim 1, enantiomers thereof, pharmaceutically acceptable salts thereof, or mixtures thereof, wherein R1 is C6-C14aryl, C6-C14heteroaryl, (C6-C14aryl)-(C1-C6alkyl), C3-C8cycloalkyl, (C3-C8heterocycloalkyl)-(C1-C6alkyl), C1-C6alkyl, (C6-C14aryl)-(C1-C6alkenyl), or C3-C8heterocycloalkyl.

### Claim 4 (depends on 1)

A compound according to claim 1, enantiomers thereof, pharmaceutically acceptable salts thereof, or mixtures thereof, wherein R1 is substituted with at least one substituent selected independently from alkyl, haloalkyl, amide, alkoxy, halogen, arylalkoxy, alkoxycarbonyl, and alkylsulfonyl.

### Claim 5 (depends on 1)

A compound according to claim 1, enantiomers thereof, pharmaceutically acceptable salts thereof, or mixtures thereof, wherein R1 is substituted with at least one substituent selected independently from C1-C6alkyl, haloC1-C6alkyl, amide, C1-C6alkoxy, halogen, (C6-C14aryl)-(C1-C6alkoxy), C1-C6alkoxycarbonyl, and C1-C6alkylsulfonyl.

### Claim 6 (depends on 1)

A compound according to claim 1, enantiomers thereof, pharmaceutically acceptable salts thereof, or mixtures thereof, wherein R2 is C6-C14aryl, C6-C14heteroaryl, C3-C8cycloalkyl, C1-C6alkyl, C3-C8heterocycloalkyl, or (C3-C8cycloalkyl)-(C1-C6alkyl).

### Claim 7 (depends on 1)

A compound according to claim 1, enantiomers thereof, pharmaceutically acceptable salts thereof, or mixtures thereof, wherein R2 is substituted with at least one alkoxy.

### Claim 8 (depends on 1)

A compound according to claim 1, enantiomers thereof, pharmaceutically acceptable salts thereof, or mixtures thereof, wherein R1 is piperidinyl, tetrahydropyranyl, phenylethyl, butyl, phenylallyl, cyclohexyl, tetrahydro-2H-thiopyranyl, morpholinylethyl, phenylmethyl, tetrahydrofuranyl, pyridinyl, methyl, cyclobutyl, phenyl, ethyl, or benzo[d][1,3]dioxolyl.

### Claim 9 (depends on 1, 8)

A compound according to claim 1 or 8, or enantiomers thereof, pharmaceutically acceptable salts thereof or mixtures thereof, wherein R2 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclohexylmethyl, methyl, isopropyl, tetrahydropyranyl, pyridinyl, or phenyl.

### Claim 10

A compound selected from:
(4-Cyclohexyl-piperazin-1-yl)-[6-(tetrahydro-pyran-4-yl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
(4-Cyclohexylmethyl-piperazin-1-yl)-[6-(tetrahydro-pyran-4-yl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
[6-(2-Ethyl-butyl)-6-aza-spiro[2.5]oct-1-yl]-(4-methyl-piperazin-1-yl)-methanone;
(4-Methyl-piperazin-1-yl)-[6-((E)-3-phenyl-allyl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
(4-Methyl-piperazin-1-yl)-(6-phenethyl-6-aza-spiro[2.5]oct-1-yl)-methanone;
(4-Methyl-piperazin-1-yl)-[6-(1-methyl-piperidin-4-yl)-6-aza-spiro[2.5]oct-1-yl]-methanone; (4-Methyl-piperazin-1-yl)-[6-(tetrahydro-pyran-4-yl)-6-aza-spiro[2.5]oct-1-yl]-methanone; (4-Cyclobutylpiperazin-1-yl)(6-(tetrahydro-2H-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone;
(4-Cyclopropylpiperazin-1-yl)(6-(tetrahydro-2H-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone;
(4-Isopropylpiperazin-1-yl)(6-(tetrahydro-2H-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone;
(4-Cycloheptylpiperazin-1-yl)(6-(tetrahydro-2H-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone;
(4-cyclopentylpiperazin-1-yl)(6-(tetrahydro-2H-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone;
4-Pyridin-2-yl-piperazin-1-yl)-[6-(tetrahydro-pyran-4-yl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
(4-Pyridin-4-yl-piperazin-1-yl)-[6-(tetrahydro-pyran-4-yl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
[4-(4-Methoxy-phenyl)-piperazin-1-yl]-[6-(tetrahydro-pyran-4-yl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
(4-Cyclohexyl-piperazin-1-yl)-(6-phenethyl-6-aza-spiro[2.5]oct-1-yl)-methanone;
(6-Cyclohexyl-6-aza-spiro[2.5]oct-1-yl)-(4-cyclohexyl-piperazin-1-yl)-methanone;
(4-Cyclohexyl-piperazin-1-yl)-[6-(1-methyl-piperidin-4-yl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
(4-Cyclohexyl-piperazin-1-yl)-(6-isopropyl-6-aza-spiro[2.5]oct-1-yl)-methanone;
(6-Cyclobutyl-6-aza-spiro[2.5]oct-1-yl)-[4-(tetrahydro-pyran-4-yl)-piperazin-1-yl]-methanone;
(6-Benzyl-6-aza-spiro[2.5]oct-1-yl)-(4-cyclohexyl-piperazin-1-yl)-methanone;
[6-(Tetrahydro-pyran-4-yl)-6-aza-spiro[2.5]oct-1-yl]-[4-(tetrahydro-pyran-4-yl)-piperazin-1-yl]-methanone;
[6-(2-Benzyloxy-ethyl)-6-aza-spiro[2.5]oct-1-yl]-(4-cyclohexyl-piperazin-1-yl)-methanone;
(4-Cyclobutyl-piperazin-1-yl)-[6-(tetrahydro-thiopyran-3-yl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
(4-Cyclobutyl-piperazin-1-yl)-(6-cyclohexyl-6-aza-spiro[2.5]oct-1-yl)-methanone;
(4-Cyclobutyl-piperazin-1-yl)-[6-(tetrahydro-pyran-3-yl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
(4-Cyclobutyl-piperazin-1-yl)-[6-(tetrahydro-furan-3-yl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
(4-Cyclobutyl-piperazin-1-yl)-[6-(2-morpholin-4-yl-ethyl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
(4-Cyclohexyl-piperazin-1-yl)-(6-pyridin-4-yl-6-aza-spiro[2.5]oct-1-yl)-methanone;
[1-(4-Cyclobutyl-piperazine-1-carbonyl)-6-aza-spiro[2.5]oct-6-yl]-acetic acid tert-butyl ester;
2-[1-(4-Cyclobutyl-piperazine-1-carbonyl)-6-aza-spiro[2.5]oct-6-yl]-N-methyl-acetamide;
(4-Cyclobutyl-piperazin-1-yl)-[6-(4-methanesulfonyl-phenyl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
(4-Cyclobutyl-piperazin-1-yl)-[6-(4-methoxy-phenyl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
4-[1-(4-Cyclobutyl-piperazine-1-carbonyl)-6-aza-spiro[2.5]oct-6-yl]-benzoic acid methyl ester;
(4-Cyclobutyl-piperazin-1-yl)[6-(6-methoxy-pyridin-2-yl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
[6-(6-Chloro-pyridin-2-yl)-6-aza-spiro[2.5]oct-1-yl]-(4-cyclobutyl-piperazin-1-yl)-methanone;
(4-Cyclohexyl-piperazin-1-yl)-[6-(2-methoxy-ethyl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
(4-Cyclobutyl-piperazin-1-yl)-(6-pyridin-2-yl-6-aza-spiro[2.5]oct-1-yl)-methanone;
(4-Cyclobutyl-piperazin-1-yl)-(6-p-tolyl-6-aza-spiro[2.5]oct-1-yl)-methanone;
4-Cyclohexyl-piperazin-1-yl)-[6-(5-trifluoromethyl-pyridin-2-yl)-6-aza-spiro[2.5]oct-1-yl]-methanone;
(6-Benzo[1,3]dioxol-5-yl-6-aza-spiro[2.5]oct-1-yl)-(4-cyclohexyl-piperazin-1-yl)-methanone;
(4-(pyridin-3-yl)piperazin-1-yl)(6-(tetrahydro-2H-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone;
(4-(2-methylpyridin-4-yl)piperazin-1-yl)(6-(tetrahydro-2H-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone; and
(4-(3-methylpyridin-4-yl)piperazin-1-yl)(6-(tetrahydro-2H-pyran-4-yl)-6-azaspiro[2.5]octan-1-yl)methanone; and
enantiomers thereof, pharmaceutically acceptable salts thereof, or mixtures thereof.

### Claim at position 11

11-13. (canceled)

### Claim 14 (depends on 1, 10)

A pharmaceutical composition comprising at least one compound according to claim 1 or 10, or enantiomers thereof, pharmaceutically acceptable salts thereof or mixtures thereof, and a pharmaceutically acceptable carrier and/or diluent.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

A method comprising treating at least one disorder selected from cognitive deficit in schizophrenia, narcolepsy, obesity, attention deficit hyperactivity disorder, and Alzheimer's disease in a warm blooded animal by administering to said animal in need of such treatment a therapeutically effective amount of at least one compound according to claim 1, or enantiomer thereof, pharmaceutically acceptable salt thereof, or mixture thereof.

### Claim 17 (depends on 16)

A method according to claim 16, wherein said disorder is cognitive deficit in schizophrenia.

### Claim 18 (depends on 16)

A method according to claim 16, wherein said disorder is Alzheimer's disease.

### Claim 19 (depends on 16)

A method according to claim 16, wherein said disorder is obesity.

### Claim 20 (depends on 16)

A method according to claim 16, wherein said disorder is attention deficit hyperactivity disorder.

### Claim 21 (depends on 16)

A method according to claim 16, wherein said disorder is narcolepsy.

### Claim 22 (depends on 14)

A method comprising treating at least one disorder selected from cognitive deficit in schizophrenia, narcolepsy, obesity, attention deficit hyperactivity disorder, and Alzheimer's disease in a warm blooded animal by administering to said animal in need of such treatment a pharmaceutical composition according to claim 14.
